• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 3/6/24: There’s No Easy Way to Stop Taking Ozempic, Navigating Changes and Trends in the Pharma Supply Chain Post-DSCSA & more


The latest news for pharma industry insiders.

Image Credit: © myskin | AdobeStock_501320442

Image Credit: © myskin | AdobeStock_501320442

Streamlining for Safety: Navigating Changes and Trends in the Pharmaceutical Supply Chain Post-DSCSA

With its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.

Data From OUtMATCH Study Show Benefits of Xolair for Common Food Allergies

The study data follows the FDA approval for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods for those aged 1 year and older with immunoglobulin E (IgE)-mediated food allergies, according to an article published by Pharmacy Times.

There’s No Easy Way to Stop Taking Ozempic

Those who go off weight-loss drugs risk regaining weight, but staying on them forever isn’t always a realistic option

Ibogaine by David Dardashti Optimizes Algorithm for Fentanyl Treatment

Ibogaine by David Dardashti has developed an optimized algorithm for fentanyl treatment that takes into account the individual's prior use of the drug and any associated potency. This algorithm also accounts for any other drugs that the individual may be consuming, addressing drug interactions with opiates in a proactive manner.

From Shubh Goel on LinkedIn:

This post is intended for a US audience.

Recently, I spoke to Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials, in liver cancer and gastric cancer, respectively.

At AstraZeneca, we believe if we can intervene earlier, we have a better chance of improving long-term outcomes for patients, so it was great to share more about our extensive clinical development program to treat GI cancers earlier.

Thanks for chatting with me, Donald Tracy, MA!


Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs